Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.thelancet.com" to "https://www.thelancet.com") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 6: | Line 6: | ||
# Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. Epub 2017 Jun 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30416-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28645776 PubMed] | # Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. Epub 2017 Jun 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30416-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28645776 PubMed] | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] |
Revision as of 22:59, 13 June 2018
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Preliminary data
Acute myeloid leukemia
- Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. Epub 2017 Jun 20. link to original article PubMed